The objective of this study is to define the role of COX-2 in altering hepatic steatosis and inflammation, features of obesity-related MASH, in genetically engineered mice lacking COX-2. The gene discussed is PTGS2; the disease is metabolic dysfunction-associated steatohepatitis.